4-(7-methyl-2,4-dipyrrolidin-1-ylpyrrolo[2,3-d]pyrimidin-6-yl)-N-(2H-tetrazol-5-yl)benzamide
C23H26N10O — CID 139683395
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(7-methyl-2,4-dipyrrolidin-1-ylpyrrolo[2,3-d]pyrimidin-6-yl)-N-(2H-tetrazol-5-yl)benzamide
4-(7-methyl-2,4-dipyrrolidin-1-ylpyrrolo[2,3-d]pyrimidin-6-yl)-N-(2H-tetrazol-5-yl)benzamide (PubChem CID 139683395) has the molecular formula C23H26N10O and a molecular weight of 458.53 g/mol. Its IUPAC name is 4-(7-methyl-2,4-dipyrrolidin-1-ylpyrrolo[2,3-d]pyrimidin-6-yl)-N-(2H-tetrazol-5-yl)benzamide.
Molecular Properties
| Compound Name | 4-(7-methyl-2,4-dipyrrolidin-1-ylpyrrolo[2,3-d]pyrimidin-6-yl)-N-(2H-tetrazol-5-yl)benzamide |
|---|---|
| PubChem CID | 139683395 |
| Molecular Formula | C23H26N10O |
| Molecular Weight | 458.53 g/mol |
| Exact Mass | 458.23 |
| IUPAC Name | 4-(7-methyl-2,4-dipyrrolidin-1-ylpyrrolo[2,3-d]pyrimidin-6-yl)-N-(2H-tetrazol-5-yl)benzamide |
| SMILES | Cn1c(-c2ccc(C(=O)Nc3nn[nH]n3)cc2)cc2c(N3CCCC3)nc(N3CCCC3)nc21 |
| InChI | InChI=1S/C23H26N10O/c1-31-18(15-6-8-16(9-7-15)21(34)26-22-27-29-30-28-22)14-17-19(31)24-23(33-12-4-5-13-33)25-20(17)32-10-2-3-11-32/h6-9,14H,2-5,10-13H2,1H3,(H2,26,27,28,29,30,34) |
| InChIKey | FOGWIQZVAGUFNT-UHFFFAOYSA-N |
| XLogP | 2.60 |
| TPSA | 120.75 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 458.53 |
| LogP ≤ 5 | 2.60 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 139683395 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.